Welcome to our dedicated page for Affimed news (Ticker: AFMD), a resource for investors and traders seeking the latest updates and insights on Affimed stock.
Affimed N.V. (Nasdaq: AFMD) is a clinical-stage biopharmaceutical leader pioneering targeted immuno-oncology therapies through its proprietary ROCK® platform. This page serves as the definitive source for Affimed news, offering investors and researchers timely updates on scientific advancements and corporate developments.
Key resources include: Press releases on clinical trial progress, regulatory milestones, and strategic partnerships; financial reports detailing earnings and R&D investments; and analyses of bispecific antibody innovations. Users gain streamlined access to Affimed's latest innate cell engager (ICE®) research and pipeline updates across hematologic and solid tumors.
Content highlights: Clinical trial results, FDA/EMA regulatory filings, collaboration announcements with biopharma partners, and presentations at major medical conferences. Bookmark this page to efficiently track Affimed's progress in advancing next-generation cancer immunotherapies.
Affimed N.V. (Nasdaq: AFMD) announced promising results for its AFM13 bispecific Innate Cell Engager, achieving a 42% Objective Response Rate (ORR) in heavily pretreated patients with relapsed or refractory CD30-positive lymphoma. The data presented at the 62nd American Society of Hematology Meeting highlighted that AFM13 was well tolerated, with evidence of NK cell activity and recruitment in patients. This development is significant given the high therapeutic need in this patient population, especially after brentuximab vedotin failure.
Affimed N.V. (Nasdaq: AFMD) announced promising results from its Phase 1b study of AFM13 in combination with KEYTRUDA for relapsed/refractory Hodgkin lymphoma. The study showed a complete response (CR) rate of 46% and an objective response rate (ORR) of 88% at the recommended dose, significantly outperforming KEYTRUDA alone, which had a CR of 22.4% and an ORR of 69%. The treatment was reported as well-tolerated with manageable adverse effects. Results suggest AFM13 could enhance current therapies.
Affimed announced a partnership with Roivant Sciences, receiving $60 million upfront and potential future milestones worth up to $2 billion.
The company ended Q3 2020 with €97.3 million in cash and equivalents, projecting runway into H1 2023.
Total revenue for Q3 was €10.5 million, a significant increase from €2.1 million year-over-year, driven by the Genentech collaboration.
Net loss decreased to €6 million, or €0.07 per share, from €10.9 million, or €0.17 per share, in Q3 2019.
Affimed N.V. (Nasdaq: AFMD) has announced a licensing agreement with Roivant Sciences to develop and commercialize novel ICE® molecules in oncology, significantly broadening its pipeline. The agreement includes a $60 million upfront payment, consisting of $40 million in cash and $20 million in newly issued shares. Affimed is eligible for up to $2 billion in future milestone payments based on the achievement of specific development and regulatory goals. This collaboration will enhance the potential of Affimed's ROCK® platform in targeting cancer therapies.
Affimed N.V. (Nasdaq: AFMD) announced a virtual presentation of preclinical data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 11, 2020. The data, focusing on the use of ICE® AFM13 in combination with various natural killer (NK) cells to target CD30-positive malignancies, showed promising results. AFM13-preloaded NK cells exhibited enhanced efficacy against tumor cells, suggesting a potential for novel immunotherapy approaches. This data supports a Phase 1 clinical evaluation currently underway.
Artiva Biotherapeutics and Affimed N.V. have entered an exclusive collaboration to explore the feasibility and activity of allogeneic NK cell combination therapies targeting EGFR and other targets. The R&D partnership will focus on preclinical assessments of Artiva's NK cell product AB-101 combined with Affimed’s ICE® molecules. This combination aims for efficient anti-tumor activity without viral transduction. The collaboration includes shared manufacturing costs and may lead to further development of selected therapeutics, marking a strategic advancement in immuno-oncology.
Affimed N.V. (NASDAQ: AFMD) announced that two abstracts for its lead innate cell engager, AFM13, have been accepted for presentation at the virtual 62nd ASH Annual Meeting, December 5-8, 2020. AFM13 is a first-in-class bispecific antibody targeting CD30 and engaging NK cells to fight cancer. The first poster details a Phase Ib/IIa study in CD30-positive lymphoma, showing a 40% Objective Response Rate (ORR) post-brentuximab vedotin failure. The second highlights a Phase II trial in Hodgkin Lymphoma with a 16.6% ORR, though it was terminated early due to recruitment issues.
Heidelberg, Germany, November 4, 2020 – Affimed N.V. (Nasdaq: AFMD) announces management participation in key investor conferences this November. The Jefferies Virtual London Healthcare Conference is scheduled for November 17-19, with a presentation on November 17 at 12:20 p.m. GMT. Additionally, Affimed will host meetings during the SVB Leerink Oncology 1x1 Day on November 19. A live webcast of the Jefferies presentation will be available on Affimed's website, followed by a 30-day replay. For more information, contact Affimed's investor relations.
Heidelberg, Germany, November 3, 2020 – Affimed N.V. (Nasdaq: AFMD) announced it will unveil third quarter 2020 results on November 10, 2020, at 8:30 a.m. ET. A conference call will follow to discuss financial outcomes and corporate updates. The call is accessible via phone and webcast, with U.S. callers dialing +1-646-741-3167, and international callers using +44 (0) 2071 928338. Interested parties can also access the live audio webcast through the company’s website, where a replay will be available for 30 days post-call.
Affimed N.V. (NASDAQ: AFMD) and NKMax America Inc. have entered a clinical collaboration to explore the combination of Affimed's innate cell engager AFM24 with NKMax's autologous NK cell product SNK01. This partnership aims to conduct a first-in-human proof-of-concept trial for patients with EGFR-expressing tumors. Preclinical data indicates a synergistic effect between the two companies' therapies. The trial will evaluate the combined efficacy of these products, potentially enhancing treatment options for patients with high mortality rates from solid tumors.
FAQ
What is the current stock price of Affimed (AFMD)?
What is the market cap of Affimed (AFMD)?
